Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 3/20 | 0.54 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ACACB | O00763 | 1/20 | 0.45 |
| ▸ | ACACA | Q13085 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL580383 | 0.91 | ADRB2 (0.51) | ADRB1ADRB2ADRB3KMT2AMEN1 | |
| SCHEMBL579438 | 0.90 | ADRB2 (0.50) | ADRB1ADRB2ADRB3KMT2AMEN1 | |
| SCHEMBL579645 | 0.89 | MEN1 (0.56) | ADRB1ADRB2ADRB3KMT2AMEN1 | |
| SCHEMBL579876 | 0.85 | ADRB1 (0.54) | ADRB1ADRB2ADRB3KMT2AMEN1 | |
| SCHEMBL579763 | 0.84 | OPRM1 (0.54) | ADRB1ADRB2ADRB3KMT2AMEN1 | |
| SCHEMBL580367 | 0.84 | ADRB1 (0.61) | ADRB1ADRB2ADRB3KMT2AMEN1 | |
| SCHEMBL579606 | 0.83 | OPRM1 (0.65) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL579608 | 0.80 | EPHX2 (0.47) | ADRB1ADRB2ADRB3HTTPOLB | |
| SCHEMBL579582 | 0.80 | EPHX2 (0.49) | ADRB1ADRB2ADRB3KMT2AHTT | |
| SCHEMBL580125 | 0.80 | LTA4H (0.51) | ADRB1ADRB2ADRB3KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735268-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-02-15 | — | — | EP | claimed |
| US-7378448-B2 | Diphenylether amide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | claimed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | claimed |
| EP-1735268-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | claimed |
| WO-2005092836-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | claimed |
| US-8338611-B2 | Opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-1735268-B1 | OPIOID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110105571-A1 | Opioid Receptor Antagonists | ELI LILLY AND COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| US-7902372-B2 | Therapy for obesity; using a secondary amino compound | ELI LILLY AND COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080207701-A1 | OPIOID RECEPTOR ANTAGONISTS | CHAPPELL MARK DONALD | 2008-08-28 | — | — | US | disclosed |
| US-7378448-B2 | Diphenylether amide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-22 | — | — | US | disclosed |
| EP-1735268-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005092836-A1 | OPIOID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207701-A1 | OPIOID RECEPTOR ANTAGONISTS | OPRD1, OPRM1, OPRK1 | ADRB1 33/4885ADRB2 78/4885ADRB3 34/4885 |
| US-20070066658-A1 | OPIOID RECEPTOR ANTAGONISTS | OPRD1, OPRM1, OPRK1 | ADRB1 33/4885ADRB2 78/4885ADRB3 34/4885 |
| US-20110105571-A1 | Opioid Receptor Antagonists | OPRD1, OPRM1, OPRK1 | ADRB1 33/4885ADRB2 78/4885ADRB3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.